1/31/2014 7:21:35 AM
French drugmaker Sanofi is suing Eli Lilly and Co for alleged patent infringements concerning its top-selling Lantus diabetes treatment, delaying the U.S. firm's plans to produce a copycat version of Lantus. Lantus is the world's most prescribed insulin product, with annual worldwide sales of about $7 billion, but is set to lose patent protection in the United States, the world's largest pharmaceutical market, in February 2015. Sanofi's lawsuit, filed on Thursday, triggers an automatic 30-month stay of approval by the U.S. Food and Drug Administration (FDA), keeping Lilly's biosimilar drug off the U.S. market until mid-2016, more than a year later than its previously expected launch date.
Help employers find you! Check out all the jobs and post your resume.
comments powered by